Abstract

<p>Supplemental material, figures and tables Supplemental Figure 1. Experimental design of the study. Supplemental Figure 2. Tumor infiltration by CD8+ T cells, CD20+ B cells and DC-LAMP+ cells correlate with prolonged survival in patients with HGSC. Supplemental Figure 3. Representative images of PD-L1 (scale bar = 100 μm) and PD-1 (Scale bar = 50 μm ) immunostaining. Supplemental Figure 4. Representative images of CTLA4 (scale bar = 50 μm) and LAG-3 (Scale bar = 50 μm ) immunostaining. Supplemental Figure 5. PD-L1 levels and infiltration by PD-1+, CTLA4+ and LAG-3+ cells were heterogeneous across samples but did not differ based on site of assessment. Supplemental Figure 6. PD-L1, PD-1 and CTLA4 expression on freshly isolated CD8+ T cells after exposure to recombinant IFNγ. Supplemental Figure 7. Representative images of 3 different samples of PD-1Lo/CD8Lo, PD-1Hi/CD8Hi, PD-1Lo/CD20/DC-LAMPLo and PD-1Hi/CD20/DC-LAMPHi immunostaining. Scale bar = 100 μm. Supplemental Figure 8: The combined prognostic impact of CD8+ T cells and PD-1+, LAG-3+ and CTLA4+ cells in HGSC. Supplemental table 1. Main clinical and biological characteristics of 20 HGSC patients in which the freshly resected tumors were analyzed using flow cytometry (Study group 2). Supplemental Table 2. The list of antibodies used for IHC staining. Supplemental table 3. The list of antibodies used for flow cytometry. Supplemental Table 4. The list of genes used by MCP counter for identification of distinct cell populations. Supplemental Table 5. The list of antibodies used for in situ immunofluorescence staining. Supplemental Table 6. Genes differentially represented in PD-1Hi vs PD-1Lo HGSCs. Supplemental Table 7. Genes differentially represented in TIM-3Hi vs TIM-3Lo HGSCs. Supplemental Table 8. Results of biostatistic analysis comparing expression of PD-L1 and density of PD-1+, LAG-3+, CTLA4+, CD8+, DC-LAMP+ and CD20+ cells in tumor microenvironment of ImmuneHi/TIM-3Hi vs ImmuneHi/TIM-3Lo and ImmuneLo/TIM-3Hi vs ImmuneLo/TIM-3Lo.</p>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.